Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Tissue Regenix CEO excited to soon be selling first products in UK

Steve Couldwell, chief executive of Tissue Regenix Group PLC (LON:TRX), caught up with Proactive's Andrew Scott following the appointment of Gareth Hywel Jones as their chief financial officer as well as the big news last month that they've been granted a Human Tissue Authority licence which will allow them to import and distribute their US-made products in the UK market.

The licence will initially be used to import CellRight’s BioRinse portfolio of bone healing products which are made at its Texas manufacturing facility.

They've also recently inked a non-exclusive three-year distribution agreement with Pennine Healthcare.

Pennine has an “established presence” in the UK orthopaedic market which should help to drive sales of Tissue’s bone and soft tissue products.

 
Meet Arix Bioscience Plc, Avacta Group Plc and Silence Therapeutics plc at our event, London , 04 October 2018. Register here »
View full TRX profile View Profile

Tissue Regenix Group PLC Timeline

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use